DNA Repair Deficiencies in Gynecologic Cancers: Implications for Therapeutic Targeting
DNA repair deficiencies present an opportunity for therapeutic targeting in gynecologic cancers.
Cells have evolved a number of mechanisms to repair damaged DNA, and deficiencies in these pathways are common in gynecologic cancers.
Tumors with alterations in DNA repair pathways, particularly homologous recombination and mismatch repair, show increased sensitivity to some therapies, including PARP inhibitors and immune checkpoint inhibitors. Genetic testing and clinical features can help identify patients most likely to benefit from therapies that target DNA repair deficiencies.
Explore the module further to learn more about therapeutic targeting of DNA repair deficiencies in gynecologic cancers—or download the module for later review offline.